Michael Urdea Net Worth

The estimated Net Worth of Michael S Urdea is at least $1.38 Mille dollars as of 30 August 2013. Michael Urdea owns over 50,000 units of Pressure BioSciences stock worth over $1,375 and over the last 12 years he sold PBIO stock worth over $0. In addition, he makes $0 as Independent Director at Pressure BioSciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Urdea PBIO stock SEC Form 4 insiders trading

Michael has made over 1 trades of the Pressure BioSciences stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of PBIO stock worth $14,500 on 30 August 2013.

The largest trade he's ever made was buying 50,000 units of Pressure BioSciences stock on 30 August 2013 worth over $14,500. On average, Michael trades about 1,250 units every 0 days since 2013. As of 30 August 2013 he still owns at least 50,000 units of Pressure BioSciences stock.

You can see the complete history of Michael Urdea stock trades at the bottom of the page.

Michael Urdea biography

Dr. Michael S. Urdea serves as Independent Director of the Company. He has served as a director of the Company since February 8, 2013. Dr. Urdea founded and is a Founder and Partner for Halteres Associates, a biotechnology consulting firm. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based diagnostics company involved in preventative personalized medicine. Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for Health, an organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. He serves as an expert consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number of biotechnology, diagnostics, venture capital and philanthropic organizations. Prior to his current business activities, Dr. Urdea founded the Nucleic Acid Diagnostics group at Chiron Corporation, and with colleagues, invented branched DNA molecules for amplification of signal in nucleic acid complexes. Application of this technology resulted in the first commercial products for quantification of human hepatitis B, hepatitis C, and human immunodeficiency viruses (HBV, HCV, and HIV, respectively). He then became business head of the Molecular Diagnostics Group and Chief Scientific Officer at Bayer Diagnostics. He continues to serve as a diagnostics industry, product development and scientific advisor to the Bill and Melinda Gates Foundation, acted as co-chair of two of the Grand Challenges grant review committees, and served as a member of its Diagnostic Forum. Dr. Urdea is an author on nearly 200 peer-reviewed scientific publications, nearly 300 abstracts and international scientific presentations, and more than 100 issued and pending patents. He received his BS in Biology and Chemistry from Northern Arizona University in Flagstaff and his Ph.D. in Biochemistry from Washington State University.

How old is Michael Urdea?

Michael Urdea is 67, he's been the Independent Director of Pressure BioSciences since 2013. There are 3 older and 4 younger executives at Pressure BioSciences. The oldest executive at Pressure BioSciences, Inc. is Richard T. Schumacher, 71, who is the Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director.

What's Michael Urdea's mailing address?

Michael's mailing address filed with the SEC is 100 Bunce Meadows Dr, Alamo, CA 94507, USA.

Insiders trading at Pressure BioSciences

Over the last 21 years, insiders at Pressure BioSciences have traded over $0 worth of Pressure BioSciences stock and bought 433,961 units worth $321,010 . The most active insiders traders include Gregory Gene Freitag, Richard T Schumacher e Kevin W Quinlan. On average, Pressure BioSciences executives and independent directors trade stock every 111 days with the average trade being worth of $342. The most recent stock trade was executed by Bradford Addison Young on 31 December 2018, trading 1,579 units of PBIO stock currently worth $3,553.

What does Pressure BioSciences do?

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.

Complete history of Michael Urdea stock trades at Pressure BioSciences

Pressure BioSciences executives and stock owners

Pressure BioSciences executives and other stock owners filed with the SEC include:

• Richard Schumacher,
  Director
• Richard T. Schumacher,
  Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director
• Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D.,
  Sr. VP of Engineering
• Dr. Alexander V. Lazarev,
  Chief Science Officer
• Daniel Shea,
  Chief Financial Officer
• Michael Urdea,
  Independent Director
• Kevin Pollack,
  Independent Director
• Vito Mangiardi,
  Independent Director
• Jeffery Peterson,
  Independent Chairman of the Board
• John B. Hollister,
  Director of Sales & Marketing
• Alexander V Lazarev,
  Director
• Bradford Addison Young,
  Chief Commerical Officer
• Jeffrey N Peterson,
  Director
• Richard Thomley,
  Chief Financial Officer
• Joseph Luis Jr Damasio,
  VP of Finance
• Calvin Albert Saravis,
  Director
• Matthew B Potter,
  Vice President of Sales
• Steven E Hebert,
  CFO / VP Finance / Asst. Treas
• J Donald Payne,
  Director
• Edward H Myles,
  Vice President of Finance/CFO
• Edmund Y Ting,
  Senior VP of Engineering
• Kevin W Quinlan,
  Director
• P Thomas Vogel,
  Director
• R Wayne Fritzsche,
  Director
• Alan D Rosenson,
  Director
• Nathan Lawrence,
  VP of Marketing and Sales
• Gregory Gene Freitag,
  Director
• Clayton Acss Llc/Il Struve,
  
• Alan Ira Goldberg,
  Director